# A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)

> **NCT02250027** · PHASE2 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 156 (actual)

## Conditions studied

- Acute Bronchitis
- Acute Exacerbations of Chronic Bronchitis

## Interventions

- **DRUG:** HL301 300mg capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02250027
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250027, "A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02250027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*